Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siplizumab for tolerance induction in living donor renal transplantation
NCT04803006Phase 2Terminated
- Sponsor
- ITB-MED
- Start
- Jan 2023
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Phase 2 trial of siplizumab in kidney transplantation (2 arms), sponsored by ITB-MED. Primary endpoint: Proportion of Patients Off Immunosuppression With Good Safety and Tolerability at 24 months. Started Jan 2023; status: terminated.
02
Drugs
siplizumab
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT04803006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04803006.